Bedaquiline fumarate: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Bedaquiline}} {{CMG}} ==Overview== ==Category== ==US Brand Names== ==FDA Package Insert== '''Description''' '''| Bedaquiline clin..." |
Gerald Chi (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Bedaquiline''' (trade name '''Sirturo''', code names '''TMC207''' and '''R207910''') is a [[diarylquinoline]] anti-[[tuberculosis]] drug, which was discovered by a team led by [[Koen Andries]] at [[Janssen Pharmaceutica]].<ref name="pmid17387738">{{cite journal | author = de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K | title = A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 | journal = Proteins | volume = 67 | issue = 4 | pages = 971–80 | year = 2007 | month = June | pmid = 17387738 | doi = 10.1002/prot.21376 | url = }}</ref> It is the first new medicine to fight TB in more than forty years,<ref>{{cite web|title=FDA Approves 1st New Tuberculosis Drug in 40 Years|url=http://abcnews.go.com/Health/wireStory/fda-approves-tuberculosis-40-years-18100650#.UOIPT-RQWe0|publisher=ABC News|accessdate=31 December 2012}}</ref><ref>{{cite web|title=F.D.A. Approves New Tuberculosis Drug|url=http://www.nytimes.com/2013/01/01/business/fda-approves-new-tuberculosis-drug.html?_r=0|publisher=New York Times|accessdate=31 December 2012}}</ref> and is specifically approved to treat [[multi-drug-resistant tuberculosis]]. | |||
==Category== | ==Category== | ||
Revision as of 15:03, 23 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Bedaquiline (trade name Sirturo, code names TMC207 and R207910) is a diarylquinoline anti-tuberculosis drug, which was discovered by a team led by Koen Andries at Janssen Pharmaceutica.[1] It is the first new medicine to fight TB in more than forty years,[2][3] and is specifically approved to treat multi-drug-resistant tuberculosis.
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages
Mechanisms of Action
References
- ↑ de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K (2007). "A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910". Proteins. 67 (4): 971–80. doi:10.1002/prot.21376. PMID 17387738. Unknown parameter
|month=ignored (help) - ↑ "FDA Approves 1st New Tuberculosis Drug in 40 Years". ABC News. Retrieved 31 December 2012.
- ↑ "F.D.A. Approves New Tuberculosis Drug". New York Times. Retrieved 31 December 2012.